Overview

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 in advanced colorectal cancer subjects.
Phase:
PHASE3
Details
Lead Sponsor:
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Treatments:
HMPL-013
regorafenib
trifluridine tipiracil drug combination